Neoadjuvant Archives

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Gallery
Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

BluePrint, Evidence, NBRST, Neoadjuvant

Pertuzumab/Trastuzumab/CT Versus Trastuzumab/CT Therapy for HER2+ Breast Cancer: Results from the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Ann Surg Oncol. 2017 Sep;24(9):2539-2546. doi: 10.1245/s10434-017-5863-x. AUTHORS: Peter Read More

kevin2024-03-25T09:14:21-07:00April 26th, 2017|BluePrint, Evidence, NBRST, Neoadjuvant|

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial
Gallery
DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

Evidence, I-SPY2, Neoadjuvant

DNA Repair Deficiency Biomarkers and the 70-Gene Ultra-High Risk Signature as Predictors of Veliparib/Carboplatin Response in the I-SPY 2 Breast Cancer Trial

PUBLICATION: NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. AUTHORS: Read More

kevin2024-02-22T12:01:50-08:00March 1st, 2017|Evidence, I-SPY2, Neoadjuvant|

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
Gallery
Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

BluePrint, Evidence, NBRST, Neoadjuvant

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping

PUBLICATION: Annals of Surgical Oncology; March 2017, Volume 24, Issue Read More

kevin2024-03-25T09:16:48-07:00October 21st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures
Gallery
Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

BluePrint, Evidence, NBRST, Neoadjuvant

Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures

PUBLICATION: Ann Surg Oncol (2016) 23: 3317. https://doi.org/10.1245/s10434-016-5329-6. AUTHORS: Peter Read More

kevin2024-03-25T09:19:31-07:00July 6th, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy
Gallery
Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

BluePrint, Evidence, NBRST, Neoadjuvant

Impact of Tumor Size on Probability of Pathologic Complete Response After Neoadjuvant Chemotherapy

PUBLICATION: Ann Surg Oncol (2016) 23: 1522. https://doi.org/10.1245/s10434-015-5030-1. AUTHORS: Paul Read More

kevin2024-03-25T09:21:21-07:00May 1st, 2016|BluePrint, Evidence, NBRST, Neoadjuvant|

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy
Gallery
Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

BluePrint, Evidence, Neoadjuvant

Molecular Subtyping Predicts Pathologic Tumor Response in Early-Stage Breast Cancer Treated with Neoadjuvant Docetaxel Plus Capecitabine with or without Trastuzumab Chemotherapy

PUBLICATION: Med Oncol. (2014) 31: 163. https://doi.org/10.1007/s12032-014-0163-9. AUTHORS: Soley Bayraktar, Read More

kevin2024-03-25T10:18:35-07:00September 4th, 2014|BluePrint, Evidence, Neoadjuvant|

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)
Gallery
Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

Evidence, NBRST, Neoadjuvant

Chemosensitivity Predicted by BluePrint 80-Gene Functional Subtype and MammaPrint in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST)

PUBLICATION: Annals of Surgical Oncology; October 2014, Volume 21, Issue Read More

kevin2024-02-20T10:41:05-08:00August 7th, 2014|Evidence, NBRST, Neoadjuvant|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy
Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

BluePrint, Evidence, Neoadjuvant

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS: Read More

kevin2024-03-25T10:46:58-07:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer
Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

Evidence, Lobular, MammaPrint, Neoadjuvant, Other

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More

kevin2024-03-25T10:51:13-07:00November 1st, 2012|Evidence, Lobular, MammaPrint, Neoadjuvant, Other|

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response
A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

BluePrint, Evidence, Neoadjuvant

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Read More

kevin2024-03-25T10:54:08-07:00May 1st, 2012|BluePrint, Evidence, Neoadjuvant|